Decera Clinical Education Oncology Podcast

In this podcast episode,Sarah Tinsley, PhD, APRN, AOCN, discusses management strategies for higher-risk and relapsed/refractory (R/R)  myelodysplastic syndromes (MDS) with a focus on the nursing perspective. Topics include: Current and ongoing clinical trials in the higher-risk and R/R MDS setting Therapies surrounding transplant Nursing considerations for managing a patient with higher risk and/o...

In this episode, Chiara Cremolini, MD, PhD, and Teresa Macarulla, MD, PhD, discuss the clinical data that inform how they select regorafenib and TAS-102 as later-line treatment for patients with mCRC, with topics including: Transitioning from second- to third-line therapy Factors in selecting among available therapies Key predictors of improved outcomes with regorafenib vs TAS-102 Presenters: Chia...

In this podcast episode from Clinical Care Options (CCO), Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss first-line treatment of patients with advanced hepatocellular carcinoma. Topics include: Atezolizumab plus bevacizumab as the current standard of care Contraindications to atezolizumab plus bevacizumab The current role of tyrosine kinase inhibitors in first-line treat...

In this episode,  Nicole Concin, MD, PhD, highlights key data for endometrial and ovarian cancers presented at the ESGO 2021 annual meeting, including: Pooled data from 7 phase III clinical trials evaluating surgical outcomes as prognostic factors for patients with high-grade serous, low-grade serous, mucinous, and clear cell ovarian cancer Update from the phase I GARNET study in patients with adv...

In this podcast episode, Julie Brahmer, MD, MSc, and Jarushka Naidoo, MB BCH BAO, MHS, answer audience questions from a live CCO webinar on evolving immunotherapy strategies for NSCLC, with topics including: Patient and/or disease-related factors considered when choosing first-line immunotherapy-based regimens Second-line therapeutic options after disease progression on an immunotherapy-based regi...

In this podcast episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss emerging data on the efficacy, safety, and clinical role of second-generation TRK inhibitors that can overcome acquired resistance to first-generation agents in  NTRK  fusion–positive solid tumors. Topics include: Mechanisms of acquired resistance to TRK inhibitor therapy Clinical trial data on the second-generation...

In this podcast episode, Jean-Yves Blay, MD, PhD, and Robin L. Jones, BSc, MBBS, MRCP, MD(Res), discuss the most important clinical trial data on leveraging TKIs as monotherapy and in combination with chemotherapy or immune checkpoint inhibitors for treatment of soft tissue sarcoma and osteosarcoma. Presenters: Jean-Yves Blay, MD, PhD Professor of Medical Oncology Department of Medicine Centre Leo...

In this episode, Philip Agop Philip, MD, PhD, FRCP, and Elena Gabriela Chiorean, MD, discuss the importance of testing for biomarkers along with thecurrent paradigm of PARP inhibitor therapy in the treatment of pancreatic cancer. Topics include: Importance of germline and somatic testing Adverse events associated with PARP inhibitors Maintenance therapy in pancreatic cancer Presenters: Philip Agop...

In this episode, Kanwal Raghav, MD, and Rachel Riechelmann, MD, PhD, discuss key data supporting contemporary dosing strategies with the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including: Individualizing therapy Clinical data and experience informing optimal dosing Key adverse events Presenters: Kanwal Raghav, MD, MBBS Associate Professor , Gastroin...

In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss key clinical data leading to FDA approvals and current indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors and ROS1-positive NSCLC. Topics include: Basket trials leading to FDA approvals of larotrectinib and entrectinib Current pan-tumor indications for first-generation TRK inhibitors in NTRK...

In this episode, Nicoletta Colombo, MD; Philipp Harter, MD, PhD; and  Alexandra Leary, MD, PhD, discuss patient cases from a live webinar on the current paradigm and long-term benefits of PARPi therapy in the treatment of ovarian cancer. Topics include: Maintenance therapy in ovarian cancer SOLO1, PRIMA, PAOLO-1 clinical data Role of bevacizumab in treatment of ovarian cancer Presenters: Nicoletta...

In this episode, listen to Guy A. Young, MD, as he counsels a teenage patient with severe hemophilia A and the patient’s mother on various available treatment options and strategies for optimizing hemophilia A prophylaxis and adherence. Topics include: Overcoming challenges to adherence Choice of standard vs extended half-life factor VIII vs emicizumab Safety and efficacy data with emicizumab Pres...

In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss the biologic rationale behind testing for NTRK fusions in patients with various solid tumors, along with clinical strategies for testing. Topics include: Differences between NTRK  fusions vs gene mutations Frequency of NTRK  fusions by age and tumor type When to test patients for NTRK  fusions and interpreting reports Method...

In this episode, Daniel W. Lin, MD; Alicia K. Morgans, MD, MPH; and David F. Penson, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in androgen deprivation therapy, with questions including: How to select between GnRH agonists and antagonists for initial androgen deprivation therapy? How should androgen receptor inhibitors be incorpo...

In this episode, Prof. Isabelle Ray-Coquard, MD, PhD, and Bernard Doger de Spéville, MD, PhD, provide expert insights on key new data from ESMO 2021 presented for endometrial and ovarian cancers including: Data from the phase III OReO/ENGOT Ov-38 trial of olaparib rechallenge in patients with recurrent ovarian cancer previously treated with a PARP inhibitor   A subgroup analysis of KEYNOTE-775, co...

In this podcast episode, Jeffrey S. Weber, MD, PhD; Allison Betof Warner, MD, PhD; and Hussein Tawbi, MD, PhD, discuss recent key data on adjuvant and neoadjuvant therapy and review the latest evidence on therapies for metastatic disease. Link to full program: https://bit.ly/3ogPjMo Follow along with the downloadable slideset: https://bit.ly/2XYNIzt Presenters:   Jeffrey S. Weber, MD, PhD Deputy D...

In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide expert insights on practice changing data from IGCS 2021 presented for endometrial, ovarian, and cervical cancers regarding: A subgroup analysis from phase III KEYNOTE-775 evaluating lenvatinib plus pembrolizumab efficacy in patients with advanced endometrial cancer and dMMR status A subgroup analysis from the phase...

In this episode, Paul G. Richardson, MD; Nina Shah, MD; and Peter M. Voorhees, MD, answer questions from a live webinar providing their thoughts on how to select the optimal therapy for patients with relapse/refractory multiple myeloma. Topics include: Treatment after first relapsed Optimal use of CAR T-cell therapy When to use selinexor and belantamab mafodotin COVID-19 vaccinations for patients...

In this episode, Dr. Joyce O’Shaughnessy, MD, leads an engaging discussion with Matthew P. Goetz, MD, and Sara Hurvitz, MD, FACP, on leveraging CDK4/6 inhibitors for the treatment of patients with metastatic HR-positive/HER2-negative breast cancer. Topics include: How the experts currently use CDK4/6 inhibitors in clinical practice Clinical implications of key studies on CDK4/6 inhibitors from ASC...

In this episode, John L. Marshall, MD, discusses current molecular testing considerations in the treatment of patients with gastrointestinal tumors, including: Current testing approaches, including IHC and PD-L1 assays and next-generation sequencing Tumor agnostic testing: MSI, TMB, and NTRK fusion testing Colon cancer: RAS, BRAF , and HER2 Gastric cancer: PD-L1, HER2 , and more Pancreatic cancer:...

In this episode, Javier Cortes, MD, PhD; Stephen R. D. Johnston, MA, FRCP, PhD; and Sara Tolaney, MD, MPH, answer questions from an  audience of healthcare professionals on topics related to leveraging CDK4/6 inhibitors for HR-positive/HER2-negative early breast cancer, including: Clinical role of Ki-67 testing Core biopsies for identifying potential benefit with neoadjuvant endocrine therapy Comb...

In this episode, Karim Fizazi, MD, PhD, and Alicia K. Morgans, MD, MPH, discuss the clinical implications of the latest data on androgen receptor–targeting agents in the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). Topics include: Updated safety and patient preference data from the ARAMIS and ODENZA trials Choice of apalutamide, darolutamide, and enzalutami...

In this podcast episode, Amy Goodrich, CRNP, discusses nursing perspectives on managing serious adverse events associated with BTK inhibitor therapy. Topics in this podcast include: Atrial fibrillation Cardiac toxicity Musculoskeletal AEs Managing risk of infections Presenter:   Amy Goodrich, RN, MSN, CRNP-AC   Research Associate/Nurse Practitioner Sidney Kimmel Comprehensive Cancer Center Johns H...

In this podcast episode, Sandra E. Kurtin, PhD, ANP-C, AOCN, discusses nursing perspectives on avoiding adverse reactions to BTK inhibitor therapy. Topics in this second of 2 podcast episodes on avoiding AEs include: Patient adherence to oral medications Lifestyle changes Monitoring, recording, and reporting of AEs The role of the nurse The role of the patient AE management Presenter:   Sandra E....

In this podcast episode,Sandra E. Kurtin, PhD, ANP-C, AOCN, discusses nursing perspectives on avoiding adverse reactions to BTK inhibitor therapy. Topics in this first of 2 podcasts on avoiding AEs include: Pharmacokinetics Drug metabolism Drug–drug interactions Drug–food interactions The role of CYP enzymes Foods to avoid Medication review Presenter: Sandra E. Kurtin, PhD, ANP-C, AOCN Director ,...